Mechanistic insights on clearance and inhibition discordance between liver microsomes and hepatocytes when clearance in liver microsomes is higher than in hepatocytes - PubMed (original) (raw)
doi: 10.1016/j.ejps.2020.105541. Epub 2020 Sep 12.
George Chang 1, Anthony Carlo 1, Jonathan J Novak 1, Michael Banker 1, Jackie Carey 1, Julie Cianfrogna 2, Heather Eng 1, Caitlin Jagla 1, Nathaniel Johnson 1, Rhys Jones 2, Samantha Jordan 1, Sarah Lazzaro 1, JianHua Liu 1, R Scott Obach 1, Keith Riccardi 1, David Tess 3, John Umland 1, Jillian Racich 1, Manthena Varma 1, Ravi Visswanathan 2, Li Di 4
Affiliations
- PMID: 32927071
- DOI: 10.1016/j.ejps.2020.105541
Mechanistic insights on clearance and inhibition discordance between liver microsomes and hepatocytes when clearance in liver microsomes is higher than in hepatocytes
Christopher Keefer et al. Eur J Pharm Sci. 2020.
Abstract
Human liver microsomes (HLM) and human hepatocytes (HHEP) are two common in vitro systems used in metabolic stability and inhibition studies. The comparison between the assays using the two systems can provide mechanistic insights on the interplay of metabolism, passive permeability and transporters. This study investigated the critical factors impacting the unbound intrinsic clearance (CLint,u) and IC50 of CYP3A inhibition between HLM and HHEP. The HLM/HHEP CLint,u ratio and HHEP/HLM IC50 ratio are inversely correlated to passive permeability, but have no correlation with P-gp efflux ratio. Cofactor-supplemented permeabilized HHEP (MetMax™) collapses the IC50 differences between HHEP and HLM. P-gp inhibitor, encequidar, shows minimal impact on CLint,u and IC50 in HHEP. This is the first study that is able to separately investigate the effects of passive permeability and efflux transport. These data collectively show that passive permeability plays a critical role in metabolism and enzyme inhibition in HHEP, while P-gp efflux has a minor role. This may be due to low functional P-gp activity in suspension HHEP under the assay conditions. Low passive permeability may limit metabolism and enzyme inhibition in HHEP, leading to lower CLint,u and higher IC50 in HHEP compared to HLM. When liver microsomes give higher CLint,u than hepatocytes, microsomes are more predictive of in vivo clearance than hepatocytes.
Keywords: CYP inhibition; Hepatocytes; IVIVE; Liver microsomes; Metabolism; P-glycoprotein efflux; Passive permeability.
Copyright © 2020 Elsevier B.V. All rights reserved.
Similar articles
- In Vitro-In Vivo Extrapolation and Scaling Factors for Clearance of Human and Preclinical Species with Liver Microsomes and Hepatocytes.
Tess D, Chang GC, Keefer C, Carlo A, Jones R, Di L. Tess D, et al. AAPS J. 2023 Apr 13;25(3):40. doi: 10.1208/s12248-023-00800-x. AAPS J. 2023. PMID: 37052732 - The Disconnect in Intrinsic Clearance Determined in Human Hepatocytes and Liver Microsomes Results from Divergent Cytochrome P450 Activities.
Bapiro TE, Martin S, Wilkinson SD, Orton AL, Hariparsad N, Harlfinger S, McGinnity DF. Bapiro TE, et al. Drug Metab Dispos. 2023 Jul;51(7):892-901. doi: 10.1124/dmd.123.001323. Epub 2023 Apr 11. Drug Metab Dispos. 2023. PMID: 37041083 - Evaluation of the Disconnect between Hepatocyte and Microsome Intrinsic Clearance and In Vitro In Vivo Extrapolation Performance.
Williamson B, Harlfinger S, McGinnity DF. Williamson B, et al. Drug Metab Dispos. 2020 Nov;48(11):1137-1146. doi: 10.1124/dmd.120.000131. Epub 2020 Aug 26. Drug Metab Dispos. 2020. PMID: 32847864 - Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.
Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. Iwatsubo T, et al. Pharmacol Ther. 1997;73(2):147-71. doi: 10.1016/s0163-7258(96)00184-2. Pharmacol Ther. 1997. PMID: 9131722 Review. - Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems.
Hallifax D, Houston JB. Hallifax D, et al. Curr Drug Metab. 2009 Mar;10(3):307-21. doi: 10.2174/138920009787846341. Curr Drug Metab. 2009. PMID: 19442091 Review.
Cited by
- Characterization and Applications of Permeabilized Hepatocytes in Drug Discovery.
Zhang S, Orozco CC, Tang LWT, Racich J, Carlo AA, Chang G, Tess D, Keefer C, Di L. Zhang S, et al. AAPS J. 2024 Mar 28;26(3):38. doi: 10.1208/s12248-024-00907-9. AAPS J. 2024. PMID: 38548986 - Design of Next-Generation DGAT2 Inhibitor PF-07202954 with Longer Predicted Half-Life.
Filipski KJ, Edmonds DJ, Garnsey MR, Smaltz DJ, Coffman K, Futatsugi K, Lee J, O'Neil SV, Wright A, Nason D, Gosset JR, Orozco CC, Blackler D, Fakhoury G, Gutierrez JA, Perez S, Ross T, Stock I, Tesz G, Dullea R. Filipski KJ, et al. ACS Med Chem Lett. 2023 Oct 2;14(10):1427-1433. doi: 10.1021/acsmedchemlett.3c00330. eCollection 2023 Oct 12. ACS Med Chem Lett. 2023. PMID: 37849537 Free PMC article. - Quantitative Translation of Substrate Intrinsic Clearance from Recombinant CYP1A1 to Humans.
Di L. Di L. AAPS J. 2023 Oct 5;25(6):98. doi: 10.1208/s12248-023-00863-w. AAPS J. 2023. PMID: 37798423 - In Vitro-In Vivo Extrapolation and Scaling Factors for Clearance of Human and Preclinical Species with Liver Microsomes and Hepatocytes.
Tess D, Chang GC, Keefer C, Carlo A, Jones R, Di L. Tess D, et al. AAPS J. 2023 Apr 13;25(3):40. doi: 10.1208/s12248-023-00800-x. AAPS J. 2023. PMID: 37052732 - Study on In Vitro Metabolism and In Vivo Pharmacokinetics of Beauvericin.
Yuan Y, Meng G, Li Y, Wu C. Yuan Y, et al. Toxins (Basel). 2022 Jul 12;14(7):477. doi: 10.3390/toxins14070477. Toxins (Basel). 2022. PMID: 35878215 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous